drugset

drugset / Trial / NCT00864981

A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions

NCT00864981 ↗

Phase 1 Completed 32 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 150 mg SR Tablets under fasting conditions.

Timeline

Start: 2005-09
Primary completion: 2005-10
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupropion	Small molecule	150 mg	—

Indications